 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Hanmi Pharmaceutical Co. and Beijing Hanmi Pharmaceutical Co. announced on the 22nd that they will begin clinical trials of next-generation immunocancer drugs (BH3120) using their own dual antibody technology "Pentambody."
Hanmi Pharmaceutical has recently been approved by the Ministry of Food and Drug Safety for a Phase 1 clinical trial plan (IND) for the next-generation immuno-cancer drug BH3120 in Korea. Earlier, Hanmi Pharmaceutical received IND approval for the same candidate material from the US Food and Drug Administration (FDA) in May.
BH3120, which is being jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, is a new drug candidate substance applied with "Petambody," a dual antibody platform technology that combines one antibody to two different targets at the same time. Through this, it has the advantage of both immuno-cancer treatment that activates immune cells and targeted anti-cancer treatment that only attacks cancer cells.
Hanmi Pharmaceutical announced the results of a study at the American Cancer Research Association (AACR) held in April this year that showed a clear decoupling of immune activity between cancer tissue and normal tissue. This showed the possibility of developing a new immune anticancer drug that minimizes the side effects of existing immune anticancer drugs.
Based on the results of such a preclinical study, Hanmi Pharmaceutical plans to launch Phase I global clinical trials in Korea and the United States at the same time this year.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
